Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2017-06-01
סדרה:	Blood Advances
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!